Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients

<div>Virologic response (viral load (VL) &lt; 50 copies/mL) over time to Week 48 (intent-to-treat noncompleter equals failure: NC = F). NC = F missing values after discontinuation imputed with change = 0. Last observation was carried forward otherwise. ATV/r: atazanavir/ritonavir; CI: confidence interval; VL: viral load.</div>

AIDS Research and Treatment

fig5

Figure 5

Figure 5: Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients 

Figure 5 | Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients 